Sutro Biopharma (STRO)

• Market cap: $378M
• 1 day: -5.6%
• 5 days: -7.68%
• 1 month: 42.82%
• 3 months: 132.43%
• 6 months: 159.91%
• Year to date: 110.58%
• 1 year: 84.64%
• 5 years: -90.24%
• 10 years: -84.82%
• Sector: Healthcare
• Industry: Biotechnology

About: Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

Employees: 131